Burning Rock Biotech (BNR) Stock Price, News & Analysis

Company Overview

Burning Rock Biotech Limited is a biotechnology company focused on precision oncology. The company develops and commercializes next-generation sequencing (NGS) tests designed to help detect cancer, guide treatment decisions and monitor patients during therapy.

Its offerings include tissue- and blood-based genomic testing for cancer patients, as well as tests intended to support therapy selection, treatment monitoring and the identification of biomarkers relevant to targeted medicines and immunotherapies. Burning Rock also develops early cancer-detection technologies, including liquid-biopsy approaches that analyze circulating tumor DNA in blood samples.

Founded in 2014, Burning Rock primarily serves hospitals, physicians, pharmaceutical companies and research institutions in China. The company has also pursued international research and commercial activities, including collaborations related to oncology drug development and clinical testing. Burning Rock was founded by and is led by Dr. Han Yusheng, who serves as its chief executive officer.

Key Stats

• Today's Range: $13.23 to $13.60
• 50-Day Range: $10.04 to $18.94
• 52-Week Range: $6.79 to $41.72
• Volume: 2,392 shs
• Average Volume: 29,572 shs
• Market Capitalization: $140.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Burning Rock Biotech Stock Analysis - MarketRank™

Burning Rock Biotech scored higher than 22% of companies evaluated by MarketBeat, and ranked 810th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Burning Rock Biotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Burning Rock Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Burning Rock Biotech is -15.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Burning Rock Biotech is -15.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Burning Rock Biotech has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.47% of the float of Burning Rock Biotech has been sold short.

Short Interest Ratio / Days to Cover

Burning Rock Biotech has a short interest ratio ("days to cover") of 1.34, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Burning Rock Biotech has recently decreased by 6.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Burning Rock Biotech does not currently pay a dividend.

Dividend Growth

Burning Rock Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Burning Rock Biotech has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Burning Rock Biotech this week, compared to 1 article on an average week.

Search Interest

1 people have searched for BNR on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Burning Rock Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.30% of the stock of Burning Rock Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

30.03% of the stock of Burning Rock Biotech is held by institutions.

Company Calendar

• Last Earnings: 9/10/2026
• Today: 11/12/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BNR
• CIK: 1792267
• Web: www.brbiotech.com
• Phone: 86-185-0164-1666
• Fax: N/A
• Employees: 667
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.92 million
• Net Margins: -13.60%
• Pretax Margin: -13.48%
• Return on Equity: -12.98%
• Return on Assets: -8.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.05
• Quick Ratio: 2.90

Sales & Book Value

• Annual Sales: $77.16 million
• Price / Sales: 1.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.28 per share
• Price / Book: 1.83

Miscellaneous

• Outstanding Shares: 10,520,000
• Free Float: 7,331,000
• Market Cap: $140.23 million
• Optionable: Not Optionable
• Beta: 1.50